Loading
NASDAQHealthcareBiotechnology
Latest quote
$6.39
+$0.21 · +3.40%
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and lupus nephritis, as well as multiple sclerosis and systemic sclerosis. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
Previous close
$6.39
+$0.21 · +3.40%
Regular session · ET · Market data may be delayed.
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and lupus nephritis, as well as multiple sclerosis and systemic sclerosis. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
Day range
Current $6.39
52-week range
Current $6.39
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
32
Expensive
Sentiment
62
Bullish
Risk
70
High Risk
Momentum
60
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and lupus nephritis, as well as multiple sclerosis and systemic sclerosis. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
Day range
Current $6.39
52-week range
Current $6.39
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | 7.03M USD | 5.66M USD |
| Cost of goods sold | — | 2.13M USD | 1.71M USD | — | — |
| Gross profit | — | −2.13M USD | −1.71M USD | 7.03M USD | 5.66M USD |
| Research and development | 133.72M USD | 112.47M USD | 48.22M USD | 28.4M USD | 25.85M USD |
| Selling, general, and administrative | 36.11M USD | 30.13M USD | 12.48M USD | 8.01M USD | 6.15M USD |
| Operating expenses | 169.83M USD | 140.47M USD | 60.7M USD | 36.41M USD | 32M USD |
| Interest income | 9.09M USD | 15.36M USD | 2.28M USD | 565K USD | 1K USD |
| Interest expense | 489K USD | 142K USD | 187K USD | 65K USD | 3K USD |
| Depreciation and amortization | 1.8M USD | 2.13M USD | 1.71M USD | 1.05M USD | 586K USD |
| Operating income | −169.83M USD | −142.6M USD | −62.41M USD | −29.38M USD | −26.35M USD |
| Net income | −161.31M USD | −127.48M USD | −60.37M USD | −28.89M USD | −26.35M USD |
Company facts updated Oct 11, 2026.
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$25.00
291.24% upsideLimited analyst sample: 4 ratings. Interpret the distribution with caution.
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI11.9M0.00%2.3T USD0.03%$381.94+0.63%
iShares Russell 2000 ETFIWM6.97M0.01%78.74B USD0.19%$278.94+0.49%
Vanguard Extended Market ETFVXF3.7M0.00%95.4B USD0.05%$235+0.80%
Fidelity Enhanced Small Cap ETFFESM3.05M0.05%6.41B USD0.28%$45.46+0.46%
Vanguard Russell 2000 ETFVTWO2.04M0.01%18B USD0.06%$112.66+0.50%
iShares Biotechnology ETFIBB1.8M0.02%10.82B USD0.44%$206.49+3.00%
State Street SPDR S&P Kensho New Economies Composite ETFKOMP1.61M0.06%2.61B USD0.20%$66.35+1.13%
Schwab U.S. Small-Cap ETFSCHA1.19M0.01%21.82B USD0.03%$32.79+0.40%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFFidelity Enhanced Small Cap ETFFESMVanguard Russell 2000 ETFVTWOiShares Biotechnology ETFIBBState Street SPDR S&P Kensho New Economies Composite ETFKOMPSchwab U.S. Small-Cap ETFSCHAAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
